MetaCap

BlossomHill Therapeutics (BLSM) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $446.8 million), about 1.0 times the size. Kamada pays a dividend yielding 7.24%, while BlossomHill Therapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%KMDA+6.46%
+72%+22%-27%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%KMDA+6.46%
+65%+23%-19%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus KMDA key metrics
MetricBLSMKMDA
Share price$14.51$7.74
Market cap$461.20M$446.85M
1-day change+0.69%-1.15%
YTD return—+9.63%
1-year return—+14.67%
5-year return—+22.66%
P/E ratio (TTM)—20.37
Forward P/E—13.34
EPS (TTM)$-10.38$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)—$180.46M
Revenue growth (YoY)—+12.12%
Net income (latest FY)—$20.20M
Gross margin—42.34%
Operating margin—14.54%
Net margin—11.19%
52-week high$27.99$9.35
52-week low$11.02$6.63
Distance from 52-week high-48.16%-17.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+143.97%+77.65%
Average volume193.15K121.87K
Shares outstanding31.78M57.73M
Employees69462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

BLSM vs KMDA FAQ

Which is bigger, BlossomHill Therapeutics or Kamada?

BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $446.85M for Kamada (KMDA).

Which pays a higher dividend, BlossomHill Therapeutics or Kamada?

Kamada pays a dividend yielding 7.24%, while BlossomHill Therapeutics does not currently pay a regular dividend.

Are BlossomHill Therapeutics and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons